Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours

Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours

18 May 2017

Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.

The promising results from a clinical trial developed and run by investigators at Melanoma Institute Australia are being presented in Chicago at the world’s largest oncology conference, the American Society of Clinical Oncology (ASCO) Annual Meeting, attended by more than 30,000 delegates from around the world. 

The ground-breaking Anti-PD1 Brain Collaboration (ABC) clinical trial involved advanced melanoma patients being given a combination of two different immunotherapy drugs: nivolumab (Opdivo®) and ipilimumab (Yervoy®).

Results from an early analysis of this trial show 79% of advanced melanoma patients with brain metastases treated with the combination immunotherapy were still alive at six months. 66% of those who got nivolumab alone were also alive after six months.

Typically, patients with active brain metastases survive only four to five months and never even used to be admitted to clinical trials because their prognosis was so dire.

“This is an absolute game-changer for how we treat patients with advanced melanoma which has spread to the brain. It provides new hope to the 1,800 Australians expected to die from melanoma this year,” said Professor Georgina Long, the study’s chief investigator, Conjoint Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at The University of Sydney.

“Quite simply, having brain metastases is no longer a death sentence,” she said. “We can now offer additional years of life and also the hope of ultimately beating this disease to a significant number of people.”

In February 2016, Australia approved the use of nivolumab for advanced melanoma patients as a stand-alone treatment or in combination with ipilimumab.

However, patients with brain metastases were excluded from previous clinical trials, including the ones that led to the drugs’ approval. This was what prompted Melanoma Institute Australia to develop and run the world-first ABC trial.

“I have melanoma patients with brain metastases who would not be alive today if they had not participated in this trial,” Professor Long said.

The study also examined patients who had no previous drug therapy prior to joining the trial, and those who received previous targeted drug therapy which is effective in patients with BRAF mutations in their melanoma.

It found that the combination of nivolumab and ipilimumab was more active in patients who had not received prior targeted BRAF-directed drug therapy.

Under the current Pharmaceutical Benefits Scheme (PBS) in Australia, doctors are restricted in the order in which they can prescribe the targeted BRAF-directed drug therapies and immunotherapy as treatments for melanoma. The restrictions make it very difficult to give immunotherapy first to patients who have the BRAF mutation in their melanoma (approximately 40% of all melanoma patients).

However, this new research strongly suggests that immunotherapy should be the first-line treatment in suitable patients, in particular, those with brain metastases.

Young dad, Leigh Miller (pictured here), is just one of the patients on the ABC Trial who has had a remarkable turnaround.

MIA Co-Medical Director opens SMR Congress in USA
21 Nov 2019

MIA Co-Medical Director opens SMR Congress in USA

Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.

Highly Cited Researchers List names MIA Co-Medical Directors
20 Nov 2019

Highly Cited Researchers List names MIA Co-Medical Directors

MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.

MPA and MIA collaboration
07 Nov 2019

MPA and MIA collaboration

Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.

Community Fundraising October Wrap-Up
04 Nov 2019

Community Fundraising October Wrap-Up

It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.

Promising data for advanced melanoma patients
09 Oct 2019

Promising data for advanced melanoma patients

MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.

Melanoma Information Forum
04 Oct 2019

Melanoma Information Forum

We are delighted to partner with Melanoma Patients Australia to host a Melanoma Information Forum at The Poche Centre on 6th November.

Community Fundraising September Wrap-Up
02 Oct 2019

Community Fundraising September Wrap-Up

Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.

Notice for Supporters to Submit to PBAC
26 Sep 2019

Notice for Supporters to Submit to PBAC

Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.

Tune into Jay's Longest Melanoma March Channel 10 documentary
16 Sep 2019

Tune into Jay's Longest Melanoma March Channel 10 documentary

Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.

Professor Georgina Long Co-Medical Director named Women of Influence in Australian Financial Review Top 100 List
11 Sep 2019

Professor Georgina Long Co -Medical Director named Women of Influence in AFR Top 100 List

We are proud to announce that our Professor Georgina Long Co -Medical Director Melanoma Institute Australia has been named in the Top 100 Financial Review 2019 Women of Influence.

Community Fundraising August Wrap-Up
04 Sep 2019

Community Fundraising August Wrap-Up

It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships
02 Sep 2019

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships

They are a formidable team - in work and in play  –  and one set to make history on both fronts.

Melanoma Institute Australia hosts first SunSafe Student Ambassador Program for 2019
30 Aug 2019

Melanoma Institute Australia hosts SunSafe Student Ambassador Programs 2019

This week, Melanoma Institute Australia hosted the first of six SunSafe Student Ambassador Programs for 2019.

Tags: SunSafe
Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma
23 Aug 2019

Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma

Federal government urged to provide certainty of access to immunotherapy for high risk melanoma patients.

Team Melanoma smashes City2Surf
16 Aug 2019

Team Melanoma smashes City2Surf

We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!

Ready to run over melanoma at City2Surf 2019
08 Aug 2019

Ready to run over melanoma at City2Surf 2019

Lauren O'Brien tells us why she's running for a cause close to her heart

Community Fundraising July Wrap-Up
01 Aug 2019

Community Fundraising July Wrap-Up

MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in the month of July that are helping us move closer to our goal of zero deaths from melanoma.

Breast cancer drug may hold key to tackling most deadly type of melanoma
23 Jul 2019

Breast cancer drug may hold key to tackling most deadly type of melanoma

An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a type of breast cancer may hold the key to treating an aggressive and deadly form of melanoma.

MIA takes centre stage at leading cancer conference
05 Jun 2019

MIA takes centre stage at leading cancer conference

Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma is treated .

International Clinical Trials Day 2019
20 May 2019

International Clinical Trials Day 2019

Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.